Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy

Liver Failure Clinical Trial

— MODHEP1  

Official title:

Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy in Non Cirrhotic Patient

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02390713
• Other study ID #: P131002
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 18, 2015
• Est. completion date: December 2020

Study information

• Verified date: April 2019
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Eric VIBERT, MD, PhD
• Phone: +33 (0)6 60 64 96 97
• Email: eric.vibert[@]pbr.aphp.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This ring aimed to preserve an intra-hepatic porto-caval gradient inferior to 5 mm Hg during and after major hepatectomy (48h) to protect the liver during the initial phases of liver regeneration. Morphological features of MID-AVRTM allow its intra corporeal opening and percutaneously removal after an balloon inflation with 5 ml of physiological serum. MID-AVRTM had been developed in pig where it had proved its efficiency to improve liver function after 75% hepatectomy and its capacity to be removed percutaneously. Aim of this feasibility study (Phase I/II) is to prove in series of 3 evaluable patients (Phase A) then 6 evaluable patients (Phase B) that MID-AVRTM could be used in human without deleterious consequence. In phase A, MID-AVRTM is dispose around the portal vein before and during a major hepatectomy performed on healthy liver and removed before abdominal closure. If phase A results confirmed that MID-AVRTM well modulates portal pressure and is easily opened and removed by acute inflation, the phase B will be started. In phase B, MID-AVRTM will be dispose around the portal vein before major hepatectomy on healthy liver and conserved 48 hours before to be removed percutaneously at the operating room.

Description:

Preserving liver function is vital, especially after hepatectomy, the main curative treatment of liver tumor. An hepatectomy that preserved a remnant liver volume < 0.5% of the body weight is associated with a very high risk of post-operative liver failure. In such situation, liver volume is not sufficient to support local hemodynamic consequences of the hepatectomy that is responsible of intrahepatic endothelial cell injury that impaired liver function and regeneration. To date, preoperative vein embolization (PVE) associated or not to liver transection (ALPSS procedure) that increased future remnant liver from 20% to 90% is the only method to prevent this complication. Even this preparation is necessary for the moment, PVE increased cancer cell proliferation and is associated with lower recurrence free survival than without PVE. Despite a potential PVE, POLF occurred in 5% to 7% after major hepatectomy and stayed the first cause of death after hepatectomy. It has been demonstrated that portal pressure superior to 20 mm Hg and/or porto-caval gradient superior to 12 mm Hg at the end of hepatectomy was associated to the occurrence of POLF. Aim to avoid this acute intra hepatic portal hypertension associated to major hepatectomy that is associated with an early liver endothelial cell injury, we had developed an silicon ring to dispose around the portal vein that contained an circular inflatable balloon to narrow precisely the portal vein lumen (MID-AVRTM).

Phase A: Tolerance and functionality of MID-AVR during surgery Each procedure will be filmed. Phase B: Tolerance and functionality of MID-AVR after surgery Each procedure will be filmed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 2020
• Est. primary completion date: April 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• French resident affiliated to Social Insurance

• Major hepatectomy (Phase A)

• Major hepatectomy that preserved only one hepatic vein (Phase B)

• Remnant liver volume > 0.5% of the body weight

Exclusion Criteria:

• Age > 80 (Phase A) and Age > 70 (Phase B)

• Cirrhotic patient (F4)

• Repeat hepatectomy

• Patient who required a portal vein resection

• History of deep venous thrombosis

• History of portal thrombosis

Related Conditions & MeSH terms

• Hepatic Insufficiency
• Liver Failure
• Major Hepatectomy

Intervention

Device:
• MID-AVR
Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed. Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography.

Locations

Country	Name	City	State
France	AP-HP, Paul Brousse Hospital, Centre Hepato-Biliaire	Villejuif

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Medical Innovation Developpement (MID)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success of MID-AVR positioning	Phase A: Feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Each procedure will be filmed.	intraoperative
Primary	Persistence of an hepatopetal portal flow at bi-daily ultrasonography	Phase B: Persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR	during the 48 hours after the liver surgery
Secondary	Portal pressure measured upstream and downstream the MID-AVR	Phase A	intraoperative
Secondary	Portal flow measured downstream the MID-AVR	Phase A	intraoperative
Secondary	Liver perfusion assessed by intraoperative contrast enhanced ultrasonography	Phase A	intraoperative
Secondary	Reliability of MID-AVR opening by balloon inflation and removal from the portal vein by smooth traction on the tube that is connected to MID-AVR.	Phase A Each procedure will be filmed.	intraoperative
Secondary	Occurrence of POLF (Bilirubin > 50 µmol/L and PT < 50% )	Phase B	at postoperative day 3
Secondary	Occurrence of post-operative hemorrhage (decrease in haemoglobin that required red pack cell transfusion)	Phase B	at postoperative day 3
Secondary	Occurrence of Post-operative biliary fistulae (Bilirubin concentration in fluid drainage greater than 3 fold the plasmatic bilirubin rate)	Phase B	at postoperative day 3
Secondary	Reliability of MID-AVR opening by balloon inflation and percutaneously removal from the portal vein by smooth traction on the tube that is connected to MID-AVR.	Phase B Removal will be done at the operating room under neurolept analgesia and local anesthesia under radiological control. Each procedure will be filmed.	at postoperative day 3